Nancy Allen, NP
Family · Lone Tree, CONPI 1992062574
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,048 of the $21,168 with a category attached, or 61.6%. Dexcom, Inc. accounts for 88.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $18,869 and has fallen 95.9% since, to $780 in 2025. Among family clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $160.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$19K
- AbbVie$757
- Neurocrine Biosciences, Inc.$418
- Alkermes, Inc.$217
- Teva Pharmaceuticals USA, Inc.$169
- Novo Nordisk$162
- plus $761 from 10 others
What the payments were for
- Speaking & faculty fees$13,04862%
- Travel & lodging$4,77523%
- Food & beverage$3,33316%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 34 | $18,682 |
| AbbVie | 35 | $757 |
| Neurocrine Biosciences, Inc. | 15 | $418 |
| Alkermes, Inc. | 10 | $217 |
| Teva Pharmaceuticals USA, Inc. | 6 | $169 |
| Novo Nordisk | 4 | $162 |
| Supernus Pharmaceuticals, Inc. | 4 | $162 |
| Axsome Therapeutics, Inc. | 3 | $151 |
| E.r. Squibb & Sons, L.L.C. | 7 | $150 |
| Otsuka America Pharmaceutical, Inc. | 5 | $90 |
| Masimo Corporation | 1 | $75 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $42 |
| Lilly USA, LLC | 2 | $37 |
| Johnson & Johnson | 2 | $32 |
| AstraZeneca | 1 | $12 |
| Corium, LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$17,705
- VRAYLAR$124
- QELBREE$123
- Wegovy$116
- Auvelity$103
How this compares
$21,168 in reported general payments places this provider in the 95th percentile of 2,182 family providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 47 | $373,112 |
| Invega SustennaPaliperidone Palmitate | 41 | $138,907 |
| Abilify MaintenaAripiprazole | 35 | $80,547 |
| AustedoDeutetrabenazine | 23 | $74,440 |
| VraylarCariprazine Hcl | 31 | $59,852 |
| Aripiprazole | 140 | $8,839 |
| Divalproex Sodium ErDivalproex Sodium | 94 | $7,110 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $5,041 |
| Risperidone | 227 | $4,448 |
| Trazodone Hcl | 206 | $4,083 |
| Divalproex Sodium | 52 | $3,906 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 101 | $3,867 |
| Duloxetine Hcl | 142 | $3,548 |
| Quetiapine Fumarate | 148 | $3,478 |
| Buspirone Hcl | 180 | $3,326 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $418 | $373,11247 claims |
| Johnson & JohnsonInvega Sustenna | $32 | $138,90741 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $90 | $80,54735 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $169 | $74,44023 claims |
| AbbVieVraylar | $757 | $59,85231 claims |
| Lilly USA, LLCOlanzapine | $37 | $3,275135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,182 family providers in Colorado.
Other family in Lone Tree
- Linda HollymanLone Tree$16K
- Corinne YoungColorado Springs$272K
- Margaret MachaffieColorado Springs$97K
- April RossGrand Junction$95K
- Jeannette LillerColorado Springs$74K
- Teal MeffordThornton$63K
- Jacquita JordanColorado Springs$52K
- Stephanie HanenbergColorado Springs$40K
- Courtney WeirFort Collins$30K
- Katie NadingDenver$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.